|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:approvalYear
|
1987
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N06AB03
|
|
gptkbp:availableOn
|
gptkb:tablet
capsule
oral solution
|
|
gptkbp:brand
|
gptkb:Prozac
gptkb:Rapiflux
gptkb:Sarafem
Selfemra
|
|
gptkbp:CASNumber
|
54910-89-3
|
|
gptkbp:chemicalFormula
|
C17H18F3NO
|
|
gptkbp:contraindication
|
concomitant use with MAOIs
hypersensitivity to fluoxetine
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:discoveredBy
|
gptkb:Bryan_Molloy
gptkb:David_T._Wong
|
|
gptkbp:discoveredIn
|
1972
|
|
gptkbp:drugClass
|
selective serotonin reuptake inhibitor
|
|
gptkbp:eliminationHalfLife
|
1 to 3 days (fluoxetine), 4 to 16 days (norfluoxetine)
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:genericName
|
gptkb:fluoxetine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Prozac
|
|
gptkbp:indication
|
gptkb:obsessive-compulsive_disorder
gptkb:panic_disorder
gptkb:major_depressive_disorder
gptkb:bulimia_nervosa
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:MAO_inhibitors
other serotonergic drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:United_States
|
|
gptkbp:marketedIn
|
over 90 countries
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patentExpired
|
2001
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children (OCD and depression)
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
suicidal thoughts (in young people)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
headache
insomnia
dry mouth
sexual dysfunction
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:bfsLayer
|
5
|